Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 7/20 | 1.00 |
| ▸ | MGLL | Q99685 | 6/20 | 0.68 |
| ▸ | FAAH | O00519 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8779419 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL7785894 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43882 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL1574552 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43969 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779453 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL24939859 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6934781 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL3291535 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779402 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110498993-B | Porous PVA/cellulose nanocrystalline hydrogel and preparation method thereof | 芜湖万隆新材料有限公司 | 2020-05-19 | — | — | CN | claimed |
| WO-2025229086-A1 | ADHESIVE COSMETIC COMPOUNDS AND USES THEREOF | SKINOSIVE (FR) | 2025-11-06 | — | — | WO | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-109232743-B | Long-acting hypoglycemic weight-loss peptide, preparation method thereof and application thereof as medicine | 中国药科大学 | 2021-08-06 | — | — | CN | disclosed |
| CN-107253985-B | Design and application of long-acting hypoglycemic peptide | 中国药科大学 | 2021-03-09 | — | — | CN | disclosed |
| CN-109824771-B | Hypoglycemic peptide and application thereof | 中国药科大学 | 2020-06-30 | — | — | CN | disclosed |
| CN-109694404-B | Hypoglycemic peptide and application thereof | 中国药科大学 | 2020-06-09 | — | — | CN | disclosed |
| CN-110498993-B | Porous PVA/cellulose nanocrystalline hydrogel and preparation method thereof | 芜湖万隆新材料有限公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2020019813-A1 | LONG-ACTING OXYNTOMODULIN HYBRID PEPTIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 中国药科大学 | 2020-01-30 | — | — | WO | disclosed |
| EP-1016659-B1 | Bismaleimides comprising mesogenic groups and oligomeric liquid crystalline bismaleimides | DAINIPPON INK & CHEMICALS (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6169186-B1 | LIQUID CRYSTALS AND LIQUID CRYSTALLINE POLYMERS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-1016659-A1 | Bismaleimides comprising mesogenic groups and oligomeric liquid crystalline bismaleimides | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | PTGS1 4773/4885PTGS2 4783/4885MGLL 883/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | PTGS1 4531/4885PTGS2 4388/4885MGLL 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.